



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Or, *et al.*  
Serial No.: 09/800,856  
Docket No.: ENP-019  
Filing Date: 3/5/2001

Group Art Unit: 1614  
Examiner: TBD

TITLE: Cyclosporins for the Treatment of Respiratory Diseases

**Box Non-Fee Amendment  
Commissioner for Patents  
Washington, D.C. 20231**

RECEIVED  
FEB 19 2002  
TECH CENTER 1600/2300


TRANSMITTAL LETTER

Dear Sir/Madam:

Enclosed herewith for filing in the above – referenced patent application are the following executed documents:

1. Change of Correspondence Address Application (PTO/SB/122);
2. Power of Attorney or Authorization of Agent (PTO/SB/81); and
3. Statement Under 37 CFR 3.73(b) (PTO/SB/96).

Respectfully submitted  
ENANTA PHARMACEUTICALS, Inc.

  
Sandhya L. Kalkunte  
Registration No. 46,466

January 30, 2002  
Enanta Pharmaceuticals, Inc.  
500 Arsenal Street  
Watertown, MA 02472  
Phone: (617) 607-0800  
Fax: (617) 607-0535

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited today with the United States Postal Service as First Class Mail in an envelope addressed to: Box Non-Fee Amendment, Commissioner for Patents, Washington, D.C. 20231.

  
Date: 1/30/02